Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Feb 1;74(2):480-488.
doi: 10.1093/jac/dky433.

Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial

Darrell H S Tan  1   2   3   4 , Janet M Raboud  5   6 , Leah Szadkowski  7 , Beatriz Grinsztejn  8 , José Valdez Madruga  9 , Maria Ines Figueroa  10 , Pedro Cahn  10 , Simon E Barton  11 , Amanda Clarke  12 , Julie Fox  13 , Wendy Zubyk  14 , Sharon L Walmsley  3   4   6   14 ; VALIDATE Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial

Darrell H S Tan et al. J Antimicrob Chemother. .

Abstract

Objectives: To determine the impact of valaciclovir on HIV disease progression in treatment-naive HIV-positive adults.

Methods: In this fully blind, multicentre, 1:1 randomized placebo-controlled trial, treatment-naive HIV-1-positive adults with CD4 counts 400-900 cells/mm3 and not meeting contemporaneous recommendations for combination ART (cART) were randomized to valaciclovir 500 mg or placebo twice daily, and followed quarterly until having two consecutive CD4 counts ≤350 cells/mm3 or initiating cART for any reason. The primary analysis compared the rate of CD4 count decline by study arm after adjusting for baseline CD4 count and viral load (VL). Secondary analyses compared the rate of CD4 percentage decline, HIV VL, herpes simplex virus (HSV) recurrences and drug-related adverse events. The trial closed after release of the START trial results in August 2015.

Results: We enrolled 198 participants in Canada, Brazil, Argentina and the UK. Median (IQR) age was 35 (30-43) years. Baseline CD4 count was 592 (491-694) cells/mm3 and VL was 4.04 (3.5-4.5) log10 copies/mL. Over 276 person-years of follow-up, CD4 counts declined by 49 cells/mm3/year in the valaciclovir arm versus 58 cells/mm3/year in the placebo arm (P = 0.65). No differences were seen in the rate of change in CD4 percentage (-1.2%/year versus -1.7%/year, P = 0.34). VL was 0.27 log10 copies/mL lower in valaciclovir participants overall (P<0.001). Placebo participants had more HSV recurrences (62 versus 21/100 person-years, P < 0.0001) but similar rates of grade ≥2 drug-related adverse events.

Conclusions: Unlike prior trials using aciclovir, we found that valaciclovir did not slow CD4 count decline in cART-untreated adults, although power was limited due to premature study discontinuation. Valaciclovir modestly lowered HIV VL.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participant flow diagram.
Figure 2.
Figure 2.
CD4 count over time by study arm.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gray RH, Wawer MJ, Sewankambo NK. et al. Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. Rakai Project Team. AIDS 1999; 13: 2113–23. - PubMed
    1. Mole L, Ripich S, Margolis D. et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176: 766–70. - PubMed
    1. Schacker T, Zeh J, Hu H. et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186: 1718–25. - PubMed
    1. Zuckerman RA, Lucchetti A, Whittington WLH. et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196: 1500–8. - PubMed
    1. Nagot N, Ouédraogo A, Foulongne V. et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356: 790–9. - PubMed

Publication types